Danish psychiatric research hospital will study the effects of Filament’s natural psilocybin drug candidate for treating alcohol use disorder VANCOUVER, BC, Jan. 18, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical–stage natural psychedelic drug development company, today announced the approval of a clinical trial in partnership with…


Previous articleNuminus Wellness Inc. Reports Q1 2023 Results
Next articleBexson Biomedical Issued USPTO Patent on Proprietary Formulation Technology, SEVALENT™